3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree

AbbVie’s pending acquisition of Apogee Therapeutics underscores renewed appetite among large-cap pharma buyers for de-risked clinical assets. The deal signals that strategic premiums remain available in biotech, supporting valuations for late-stage healthcare names. The news is modestly positive for the sector and sentiment around M&A in pharma.

Analysis

AbbVie’s pending acquisition of Apogee Therapeutics underscores renewed appetite among large-cap pharma buyers for de-risked clinical assets. The deal signals that strategic premiums remain available in biotech, supporting valuations for late-stage healthcare names. The news is modestly positive for the sector and sentiment around M&A in pharma.